UBS Reiterates Buy Rating on Encompass Health Corp (EHC) Following Novo Expansion Plan Announcement

UBS analyst AJ Rice reiterated a Buy rating and $150.00 price target on Encompass Health Corp (NYSE: EHC).

The analyst commented, "On November 21st, EHC announced plans for a de novo expansion in Indiana. The plans call for the building of a freestanding, 50-bed inpatient rehabilitation hospital to be located in Fishers, Indiana. The facility will serve patients in Hamilton County and surrounding communities recovering from debilitating illnesses and injuries, including strokes and other neurological disorders, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions. The company noted the hospital will also offer all private patient rooms, a spacious therapy gym with advanced rehabilitation technologies, an activities of daily living suite, in-house dialysis suite, dining room, pharmacy and therapy courtyard. The hospital is expected to open in 2027 and will be part of Encompass Health's national network of rehabilitation hospitals. This facility will complement its existing locations in Indiana, including its Health Deaconess Rehabilitation Hospital in Newburgh and its satellite location, Encompass Health Deaconess Rehabilitation Hospital, downtown Evansville...Our price target of $150 is based on ~12x our 2027E EBITDA-NCI estimate."

For an analyst ratings summary and ratings history on Encompass Health Corp click here. For more ratings news on Encompass Health Corp click here.

Shares of Encompass Health Corp closed at $114.35 yesterday.

You May Also Be Interested In

• Bumble Inc. (BMBL) PT Lowered to $3.20 at Citi
• MicroVision launches public offering of shares and warrants
• Diginex reports 77% revenue rise but $31M net loss in FY2026